Baseline demographics and clinical characteristics of VERTIS CV patients with CKD stage 3*
| Characteristic† | Placebo (N=598) | Ertugliflozin 5 mg (N=618) | Ertugliflozin 15 mg (N=560) |
| Age—years | 68.0 (7.5) | 68.3 (7.7) | 68.2 (7.5) |
| Male—n (%) | 395 (66.1) | 396 (64.1) | 351 (62.7) |
| Race—n (%)‡ | |||
| White | 514 (86.0) | 523 (84.6) | 493 (88.0) |
| Black | 17 (2.8) | 21 (3.4) | 9 (1.6) |
| Asian | 43 (7.2) | 55 (8.9) | 35 (6.3) |
| Other | 24 (4.0) | 19 (3.1) | 23 (4.1) |
| Region—n (%) | |||
| North America | 191 (31.9) | 189 (30.6) | 169 (30.2) |
| South America | 46 (7.7) | 42 (6.8) | 49 (8.8) |
| Europe | 271 (45.3) | 290 (46.9) | 262 (46.8) |
| Asia | 46 (7.7) | 49 (7.9) | 32 (5.7) |
| South Africa | 28 (4.7) | 37 (6.0) | 30 (5.4) |
| Australia/New Zealand | 16 (2.7) | 11 (1.8) | 18 (3.2) |
| Body mass index—kg/m2 | 32.6 (5.6) | 32.3 (5.3) | 32.4 (5.7) |
| Duration of type 2 diabetes—years | 16.4 (9.3) | 15.3 (8.8) | 15.2 (8.7) |
| Glycated hemoglobin—% | 8.2 (0.9) | 8.2 (0.9) | 8.2 (0.9) |
| eGFR—mL/min/1.73 m2§ | 49.0 (7.5) | 49.6 (7.4) | 49.4 (7.7) |
| Albuminuria—n (%) | |||
| Normal-albuminuria (<30 mg/g) | 285 (47.7) | 302 (48.9) | 268 (47.9) |
| Micro-albuminuria (≥30–≤300 mg/g) | 207 (34.6) | 209 (33.8) | 178 (31.8) |
| Macro-albuminuria (>300 mg/g) | 92 (15.4) | 91 (14.7) | 95 (17.0) |
| Unknown | 14 (2.3) | 16 (2.6) | 19 (3.4) |
| Systolic blood pressure—mm Hg | 132.7 (15.2) | 134.7 (14.8) | 133.6 (14.5) |
| Hypertension—n (%) | 571 (95.5) | 589 (95.3) | 524 (93.6) |
| Dyslipidemia—n (%) | 489 (81.8) | 496 (80.3) | 445 (79.5) |
| Coronary artery disease—n (%) | 480 (80.3) | 491 (79.4) | 436 (77.9) |
| Cerebrovascular disease—n (%) | 138 (23.1) | 153 (24.8) | 147 (26.3) |
| Peripheral arterial disease—n (%) | 123 (20.6) | 113 (18.3) | 111 (19.8) |
| Antihyperglycemic medications—n (%) | |||
| None | 3 (0.5) | 5 (0.8) | 0 (0.0) |
| Metformin | 382 (63.9) | 385 (62.3) | 348 (62.1) |
| Insulin | 357 (59.7) | 370 (59.9) | 308 (55.0) |
| Sulfonylurea | 227 (38.0) | 231 (37.4) | 219 (39.1) |
| Dipeptidyl peptidase-4 inhibitor | 72 (12.0) | 74 (12.0) | 70 (12.5) |
| Glucagon-like peptide-1 receptor agonist | 25 (4.2) | 25 (4.0) | 19 (3.4) |
*CKD stage was based on eGFR calculated using the MDRD equation.
†Values are mean±SD unless otherwise stated.
‡Race was reported by the participant.
§eGFR was calculated using the MDRD equation.
CKD, chronic kidney disease; CKD stage 3, eGFR 30–<60 mL/min/1.73 m2; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.